Drug Approval | July 17, 2025
SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Celecoxib is a nonsteroidal anti-inflammatory drug
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Subscribe To Our Newsletter & Stay Updated
